222 related articles for article (PubMed ID: 26886021)
1. Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs).
Nagel-Wolfrum K; Möller F; Penner I; Baasov T; Wolfrum U
BioDrugs; 2016 Apr; 30(2):49-74. PubMed ID: 26886021
[TBL] [Abstract][Full Text] [Related]
2. Translational read-through as an alternative approach for ocular gene therapy of retinal dystrophies caused by in-frame nonsense mutations.
Nagel-Wolfrum K; Möller F; Penner I; Wolfrum U
Vis Neurosci; 2014 Sep; 31(4-5):309-16. PubMed ID: 24912600
[TBL] [Abstract][Full Text] [Related]
3. Strategies against Nonsense: Oxadiazoles as Translational Readthrough-Inducing Drugs (TRIDs).
Campofelice A; Lentini L; Di Leonardo A; Melfi R; Tutone M; Pace A; Pibiri I
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284579
[TBL] [Abstract][Full Text] [Related]
4. Aminoglycoside-induced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy.
Zingman LV; Park S; Olson TM; Alekseev AE; Terzic A
Clin Pharmacol Ther; 2007 Jan; 81(1):99-103. PubMed ID: 17186006
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical therapies to recode nonsense mutations in inherited diseases.
Lee HL; Dougherty JP
Pharmacol Ther; 2012 Nov; 136(2):227-66. PubMed ID: 22820013
[TBL] [Abstract][Full Text] [Related]
6. Therapeutics based on stop codon readthrough.
Keeling KM; Xue X; Gunn G; Bedwell DM
Annu Rev Genomics Hum Genet; 2014; 15():371-94. PubMed ID: 24773318
[TBL] [Abstract][Full Text] [Related]
7. Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases.
Keeling KM; Bedwell DM
Wiley Interdiscip Rev RNA; 2011; 2(6):837-52. PubMed ID: 21976286
[TBL] [Abstract][Full Text] [Related]
8. Translational readthrough induction of pathogenic nonsense mutations.
Kellermayer R
Eur J Med Genet; 2006; 49(6):445-50. PubMed ID: 16740421
[TBL] [Abstract][Full Text] [Related]
9. Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms.
Ng MY; Li H; Ghelfi MD; Goldman YE; Cooperman BS
Proc Natl Acad Sci U S A; 2021 Jan; 118(2):. PubMed ID: 33414181
[TBL] [Abstract][Full Text] [Related]
10. Sense from nonsense: therapies for premature stop codon diseases.
Bidou L; Allamand V; Rousset JP; Namy O
Trends Mol Med; 2012 Nov; 18(11):679-88. PubMed ID: 23083810
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development.
Li S; Li J; Shi W; Nie Z; Zhang S; Ma F; Hu J; Chen J; Li P; Xie X
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371567
[TBL] [Abstract][Full Text] [Related]
12. Targeting Translation Termination Machinery with Antisense Oligonucleotides for Diseases Caused by Nonsense Mutations.
Huang L; Aghajan M; Quesenberry T; Low A; Murray SF; Monia BP; Guo S
Nucleic Acid Ther; 2019 Aug; 29(4):175-186. PubMed ID: 31070517
[TBL] [Abstract][Full Text] [Related]
13. Suppression of premature termination codons as a therapeutic approach.
Keeling KM; Wang D; Conard SE; Bedwell DM
Crit Rev Biochem Mol Biol; 2012 Sep; 47(5):444-63. PubMed ID: 22672057
[TBL] [Abstract][Full Text] [Related]
14. Targeting Nonsense: Optimization of 1,2,4-Oxadiazole TRIDs to Rescue CFTR Expression and Functionality in Cystic Fibrosis Cell Model Systems.
Pibiri I; Melfi R; Tutone M; Di Leonardo A; Pace A; Lentini L
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899265
[TBL] [Abstract][Full Text] [Related]
15. Mechanism and evidence of nonsense suppression therapy for genetic eye disorders.
Richardson R; Smart M; Tracey-White D; Webster AR; Moosajee M
Exp Eye Res; 2017 Feb; 155():24-37. PubMed ID: 28065590
[TBL] [Abstract][Full Text] [Related]
16. Ataluren for the Treatment of Usher Syndrome 2A Caused by Nonsense Mutations.
Samanta A; Stingl K; Kohl S; Ries J; Linnert J; Nagel-Wolfrum K
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31842393
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapeutics overcoming nonsense mutation-associated genetic diseases: medicinal chemistry of negamycin.
Taguchi A; Hamada K; Hayashi Y
J Antibiot (Tokyo); 2018 Feb; 71(2):205-214. PubMed ID: 28951602
[TBL] [Abstract][Full Text] [Related]
18. Factors Affecting Readthrough of Natural Versus Premature Termination Codons.
Beryozkin A; Nagel-Wolfum K; Banin E; Sharon D
Adv Exp Med Biol; 2023; 1415():149-155. PubMed ID: 37440028
[TBL] [Abstract][Full Text] [Related]
19. Readthrough Approach Using NV Translational Readthrough-Inducing Drugs (TRIDs): A Study of the Possible Off-Target Effects on Natural Termination Codons (NTCs) on TP53 and Housekeeping Gene Expression.
Perriera R; Vitale E; Pibiri I; Carollo PS; Ricci D; Corrao F; Fiduccia I; Melfi R; Zizzo MG; Tutone M; Pace A; Lentini L
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894764
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development.
Rowe SM; Clancy JP
BioDrugs; 2009; 23(3):165-74. PubMed ID: 19627168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
